Envarsus XR in African American Renal Transplant Recipients
Status:
Terminated
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect data prospectively on African American patients who
are taking the immunosuppressant Envarsus post kidney transplant. We are looking to see if
African American renal transplant recipients that receive Envarsus will have less tubular
injury and calcenurin inhibitor toxicity compared with patients that receive tacrolimus IR.
African americans have the higher rates of CYP3A5 which is associated with the need of higher
tacrolimus dose to achieve an adequate level and this many times is associated with signs and
symptoms of tacrolimus toxicity such as tremors, headaches and neuropathies.
The retrospective cohort will be African American patients that will be matched by age,
gender, type of kidney transplant (living vs deceased) and level of sensitization